Skip Nav Destination
1-7 of 7
Acta Haematol (2019) 141 (3): 151–155.
Published Online: 15 February 2019
...Elena Santagostino; Guy Young; Carmen Escuriola Ettingshausen; Victor Jimenez-Yuste; Manuel Carcao The development of inhibitors against factor VIII (FVIII) concentrates represents a significant treatment complication for hemophilia. Immune tolerance induction (ITI) therapy eradicates inhibitors...
Acta Haematol (1985) 73 (3): 168–172.
Published Online: 25 February 2009
... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Alkaline phosphatase Granulocytes Inhibitors Isoenzymes Leukemia Acta haemat. 73: 168-172(1985) © 1985S. Karger AG, Basel 0001-5792/85/0733-0168 $ 2.75/0 Changes...
Acta Haematol (1988) 80 (4): 210–215.
Published Online: 24 February 2009
... no effect on PMA- or collagen-induced platelet aggregation, partially inhibited aggregation triggered by ADP and strongly inhibited aggregation caused by thrombin. It is suggested that PMA exerts its effect on platelets mainly due to its ability to alter their membranes. Inhibitors Phorbol-myristate...
Acta Haematol (1995) 94 (Suppl. 1): 49–52.
Published Online: 18 February 2009
...R.C.R. Ljung The nature of the mutation in the factor IX gene is an important factor in determining whether a patient with hemophilia B will develop an inhibitor. In a series of 62 Swedish families with hemophilia B, including 30 with the severe form, approximately one third of the families...
Acta Haematol (2006) 115 (3-4): 172–179.
Published Online: 17 March 2006
...Guy Young The most serious current complication of factor replacement therapy for hemophilia patients is the development of neutralizing antibodies to the factor termed inhibitors. Patients with high-titer inhibitors frequently develop serious bleeding complications which do not respond to standard...
Acta Haematol (2000) 103 (2): 67–72.
Published Online: 19 May 2000
...Kanjaksha Ghosh; Shrimati Shetty; Anil Pathare; Dipika Mohanty Haemophilia patients with inhibitors pose a formidable challenge for patient management. This is particularly problematic in developing countries, where porcine factor VIII, FEIBA, factor VIIa or immunoadsorption column are generally...
Acta Haematol (1999) 102 (1): 42–46.
Published Online: 01 September 1999
...Hale Ören; Işın Yaprak; Gülersu İrken In 58 hemophilia A patients aged 1–18 years (mean 9.5 ± 4.7 years), the prevalence of inhibitors was found to be 27% by the Bethesda method in November 1995. Inhibitor activity was not detected in any of 14 patients with mild hemophilia while it was present...